Diana Bell Selected Research

Biomarkers (Surrogate Marker)

1/2023	Olfactory Neuroblastoma: Morphological Reappraisal and Molecular Insights with Quantum Leap in Clinical Perspectives.
1/2021	The tumor immune contexture of salivary duct carcinoma.
8/2019	Magnifying glass on spiradenoma and cylindroma histogenesis and tumorigenesis using systematic transcriptome analysis.
1/2019	Comparative transcriptome analysis of sinonasal inverted papilloma and associated squamous cell carcinoma: Out-HOXing developmental genes.
11/2018	Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline.
3/2018	Transcriptome comparison identifies potential biomarkers of spine and skull base chordomas.
10/2016	Whole-transcriptome analysis of chordoma of the skull base.
5/2016	In-depth characterization of the salivary adenoid cystic carcinoma transcriptome with emphasis on dominant cell type.
1/2015	Analysis and significance of c-MET expression in adenoid cystic carcinoma of the salivary gland.
4/2013	Head and neck adenoid cystic carcinoma: what is new in biological markers and treatment?

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Diana Bell Research Topics

Disease

65	Neoplasms (Cancer) 04/2024 - 07/2007
20	Carcinoma (Carcinomatosis) 12/2022 - 01/2010
16	Squamous Cell Carcinoma of Head and Neck 01/2023 - 06/2012
9	Adenoid Cystic Carcinoma (Cylindroma) 01/2023 - 12/2010
9	Neoplasm Metastasis (Metastasis) 01/2022 - 10/2013
6	Sinonasal undifferentiated carcinoma 04/2024 - 03/2013
6	Adenocarcinoma 01/2022 - 09/2009
4	Carcinogenesis 07/2023 - 04/2013
4	Mucoepidermoid Carcinoma 01/2016 - 04/2008
3	Olfactory Esthesioneuroblastoma (Esthesioneuroblastoma) 02/2024 - 01/2017
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 12/2022 - 11/2016
3	Disease Progression 01/2021 - 01/2010
3	Lymphatic Metastasis 01/2019 - 03/2013
2	Infections 07/2023 - 02/2020
2	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 03/2009
2	Genetic Translocation (Chromosomal Translocation) 08/2020 - 04/2013
2	Autoimmune Diseases (Autoimmune Disease) 02/2020 - 01/2020
2	Pleomorphic Adenoma 12/2019 - 09/2015
2	Chordoma 03/2018 - 10/2016
2	Residual Neoplasm 03/2013 - 04/2011
2	Pancreatic Neoplasms (Pancreatic Cancer) 11/2011 - 07/2007
1	Thyroiditis 01/2024
1	Hypothyroidism 01/2024
1	Hyperthyroidism 01/2024
1	Margins of Excision 01/2023
1	Papillomavirus Infections 01/2023
1	Acoustic Neuroma (Acoustic Neurinoma) 10/2022
1	Exanthema (Rash) 04/2022
1	Lymphadenopathy 04/2022
1	Spontaneous Remission 01/2022
1	Neuroendocrine Carcinoma 12/2021
1	Papillary Thyroid Cancer 01/2021
1	Breast Neoplasms (Breast Cancer) 01/2021
1	Triple Negative Breast Neoplasms 01/2021

Drug/Important Bio-Agent (IBA)

16	Biomarkers (Surrogate Marker)IBA 01/2023 - 03/2009
9	ParaffinIBA 10/2023 - 01/2010
7	RNA (Ribonucleic Acid)IBA 10/2023 - 06/2017
7	Proteins (Proteins, Gene)FDA Link 08/2019 - 12/2010
6	DNA (Deoxyribonucleic Acid)IBA 10/2023 - 04/2008
6	Formaldehyde (Formol)FDA Link 10/2023 - 04/2015
5	Immune Checkpoint InhibitorsIBA 01/2024 - 06/2019
5	Messenger RNA (mRNA)IBA 01/2023 - 07/2007
5	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2016 - 07/2007
4	pembrolizumabIBA 01/2023 - 01/2021
4	Transcription Factors (Transcription Factor)IBA 08/2020 - 03/2012
3	Cetuximab (Erbitux)FDA Link 04/2016 - 03/2013
3	Capecitabine (Xeloda)FDA Link 11/2011 - 07/2007
2	Keratins (Keratin)IBA 02/2024 - 03/2009
2	AntibodiesIBA 01/2023 - 06/2019
2	Androgen Receptors (Androgen Receptor)IBA 01/2022 - 12/2019
2	Estrogen ReceptorsIBA 01/2021 - 04/2011
2	Phenobarbital (Luminal)FDA Link 01/2021 - 09/2015
2	human ERBB2 proteinIBA 01/2021 - 01/2016
2	Progesterone Receptors (Progesterone Receptor)IBA 01/2021 - 04/2011
2	Nuclear Proteins (Protein, Nuclear)IBA 12/2020 - 04/2015
2	PlasticsIBA 03/2019 - 08/2013
2	MicroRNAs (MicroRNA)IBA 11/2018 - 04/2015
2	LigandsIBA 02/2014 - 03/2013
2	ErbB Receptors (EGF Receptor)IBA 03/2013 - 12/2010
2	N 30IBA 10/2010 - 01/2010
2	Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)IBA 09/2009 - 07/2007
2	Thymidine PhosphorylaseIBA 09/2009 - 07/2007
1	Interferon-gamma (Interferon, gamma)IBA 04/2024
1	Interleukin-15 (Interleukin 15)IBA 04/2024
1	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 01/2024
1	Thyroid HormonesIBA 01/2024
1	Tyrosine Kinase InhibitorsIBA 01/2024
1	ChromatinIBA 10/2023
1	avelumabIBA 01/2023
1	NivolumabIBA 01/2023
1	Axitinib (AG 013736)IBA 01/2023
1	MetalsIBA 01/2023
1	SynaptophysinIBA 01/2023
1	Chromogranin AIBA 01/2023
1	Oncogene Proteins (Oncogene Protein)IBA 12/2022
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 04/2022
1	VaccinesIBA 01/2022
1	COVID-19 VaccinesIBA 01/2022
1	Cisplatin (Platino)FDA LinkGeneric 01/2022
1	2019-nCoV Vaccine mRNA-1273IBA 01/2022
1	Docetaxel (Taxotere)FDA Link 01/2021
1	tyrosine receptor (receptor, tyrosine)IBA 01/2021
1	CarcinogensIBA 01/2021
1	Tumor Biomarkers (Tumor Markers)IBA 01/2021
1	Phosphotransferases (Kinase)IBA 01/2021
1	10-propargyl-10-deazaaminopterin FDA Link 01/2021
1	PanobinostatIBA 01/2021

Therapy/Procedure

31	Therapeutics 01/2024 - 12/2010
13	Radiotherapy 01/2023 - 07/2007
6	Drug Therapy (Chemotherapy) 01/2022 - 01/2010
5	Immunotherapy 04/2024 - 12/2020
5	Neoadjuvant Therapy 01/2023 - 01/2019
4	Neck Dissection (Radical Neck Dissection) 01/2023 - 10/2013
4	Induction Chemotherapy 04/2022 - 01/2017
2	Combined Modality Therapy 01/2022 - 06/2020
2	Adjuvant Radiotherapy 03/2016 - 01/2016
2	Chemoradiotherapy 01/2016 - 11/2011
1	Aftercare (After-Treatment) 04/2024
1	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 01/2023
1	Proton Therapy 01/2023